AJ302 is a first-in-class HDAC6 inhibitor under development for the prevention and/or treatment of chemotherapy-induced peripheral neuropathy. Phase 1 clinical trial of AJ302 will be initiated in early 2021. 

AJ302 was selected among quinazolin-2,4-dione-based hydroxamic acids designed and synthesized by scientists at AnnJi for its HDAC6 inhibition activity in vitro and in vivo, its selectivity over other HDACs, its safety profile and its drug like physiochemical properties.

It is a highly selective inhibitor of HDAC6 which promotes neurite growth and branches. The selective inhibition of HDAC6 can substantially reduce drug toxicity while maintaining on target activity. In a rat CIPN model, AJ302 reversed paclitaxel-induced allodynia, and the pain relief was maintained for two weeks after dosing which suggests restoration of neurons. AJ302 may be useful in providing a much-needed drug for the treatment and/or prevention of CIPN in cancer patients receiving chemotherapy drugs.